Crescita Therapeutics Expands with Occy Assets Buy

Crescita Therpeutc (TSE:CTX) has released an update.

Crescita Therapeutics Inc. has enhanced its market position by completing the acquisition of Occy Laboratory’s business assets, which includes manufacturing equipment, inventory, and intellectual property. The deal, valued at $0.9 million, is expected to be accretive to Crescita’s EBITDA following integration. Occy, facing bankruptcy proceedings, was approved for asset sale by the Québec Superior Court, and Crescita will maintain Occy’s commercial operations.

For further insights into TSE:CTX stock, check out TipRanks’ Stock Analysis page.